Compare Cardinal Health Inc (CAH) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs SOLAI Limited — how do they compare? Cardinal Health Inc trades at $234.16 (market cap $55.88B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Cardinal Health Inc is far larger — about 3348.1× SOLAI Limited's market cap, and Cardinal Health Inc pays a 0.86% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| CAH | SLAI | |
|---|---|---|
Market Cap | $55.88B | $16.69M |
Sector | Health | Technology |
52-Week High | $240.26 | $26.74 |
52-Week Low | $146.04 | $2.74 |
Enterprise Value | $59.91B | $16.33M |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
SLAI trades at $3.72 with no recent price change. The stock shows a bullish technical signal, but the company faces severe financial distress with negative gross and net income margins, and a net loss of $33.88 million in 2025. A reverse stock split was executed on July 6, 2026, and the NYSE has commenced delisting proceedings, creating significant uncertainty.
The outlook is highly speculative. The acquisition of a stake in NEURALAND and the launch of Solode Neo represent potential growth avenues, but the delisting risk and persistent losses overshadow any near-term upside. Investors face substantial risk of capital loss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
